COMMUNIQUÉS West-GlobeNewswire

Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.
20/03/2026
Louvain-la-Neuve, Belgium– March 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, [...]
Telix choisit le Cyclone® KIUBE d’IBA pour étendre ses capacités de production aux États‑Unis
20/03/2026
Louvain ‑ la ‑ Neuve, Belgique, le 20 mars 2026 — IBA (Ion Beam Applications S.A., EURONEXT) , leader mondial des technologies d’accélérateurs de particules et premier fournisseur mondial de solutions de production de [...]
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
20/03/2026
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818, currently in a Phase 1/2 [...]
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
19/03/2026
Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase 1b long-term extension [...]
Pacific Health Care Organization, Inc. Reports its 2025 Year-End Financial Results
19/03/2026
Irvine, CA, March 19, 2026 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) filed Tuesday with the Securities and Exchange Commission (the “SEC”) its annual report on Form 10-K [...]
Cellectis publie ses résultats financiers du quatrième trimestre 2025 et de l’exercice 2025 et une mise à jour de ses activités
20/03/2026
Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01) en cours Phase 1 : 83 % d’ORR à la dose RP2D et 100 % d’ORR dans la population cible de phase 2. Population cible de phase 2 : [...]
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
20/03/2026
SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it [...]
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
20/03/2026
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 population In target Phase 2 population: 100% of patients became eligible to transplant [...]
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
19/03/2026
-- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction – -- [...]
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025
19/03/2026
MISSISSAUGA, Ontario, March 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. Key [...]
Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
19/03/2026
REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results U.S. Commercialization Off to a Strong Start in First Full Quarter of Sales Foundation Established to Drive [...]
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
19/03/2026
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in relapsed small cell [...]
Kaida BioPharma Announces Executive Leadership Team to Advance KAD-101, Built for the Ovarian Cancer Gap
19/03/2026
FORT LAUDERDALE, Fla., March 19, 2026 (GLOBE NEWSWIRE) -- Kaida BioPharma, a biotechnology company developing targeted therapies for women with hard-to-treat gynecologic cancers, today announced its executive leadership [...]
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
19/03/2026
TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial [...]
Gain Therapeutics to Present at the 38th Annual ROTH Conference
19/03/2026
BETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
19/03/2026
CRANFORD, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“ Enzon ” or the “ Company ”) today announced that it has extended the expiration date for the exchange offer by the Company [...]
Teva Releases Q1 2026 Aide Memoire
19/03/2026
TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the “Investors” page on its website. Q 1 202 6 [...]
Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
19/03/2026
-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong financial position with approximately $535 million in cash and cash [...]
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
19/03/2026
Company announcement – No. 4 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 19, 2026 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL [...]

Pages